Victoria Langowska , 2025-05-14 17:07:00
In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Rinatabart sesutecan (Rina-S, Genmab) is an investigational folate receptor-alpha-targeted TOP01 antibody-drug conjugate.
“One of the interesting aspects of this drug — and certainly very positive aspects of this drug — is that folate receptor-alpha expression levels seem not to matter as much,” Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute and professor at Harvard Medical School, said. “The level of FR-alpha did not predict responsiveness. In other words, you can see responses at different levels of folate receptor-alpha positivity.”
Sources/Disclosures
Collapse
Source:
Healio interviews
Disclosures:
Matulonis reports consulting fees from Merck; data safety monitoring board participation for Mural Oncology and Symphogen; and scientific advisory board participation for Abbvie, Allarity, Daiichi Sankyo, Eisai, GSK, Immunogen, NextCure, Novartis, Profound Bio, Tango Therapeutics and the Ovarian Cancer Research Alliance.
